Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

The Glycogensynthase Kinase 3b (GSK-3β) Is Involved in Leukemic Transformation

Jörg Bäsecke, Anneke Lehmann, Ulla Bergholz, James McCubrey, PhD, Lorenz Trümper, Carol Stocking, Stefan Horn

Blood (2008) 112 (11): 4489.

https://doi.org/10.1182/blood.V112.11.4489.4489

Published: 2008

Journal Articles

The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate

Andrea Schüler, Maike Schwieger, Afra Engelmann, Kristoffer Weber, Stefan Horn, Ursula Müller, Michael A. Arnold, Eric N. Olson, Carol Stocking

Blood (2008) 111 (9): 4532–4541.

https://doi.org/10.1182/blood-2007-10-116343

Published: 2008

Includes: Supplemental data

Journal Articles

Mutations in the Catalytic Subunit of Class IA PI3K Are Leukemogenic In Vivo.

Stefan Horn, James A. McCubrey, Carol Stocking, Lorenz Trumper, Jorg Basecke

Blood (2007) 110 (11): 875.

https://doi.org/10.1182/blood.V110.11.875.875

Published: 2007

Journal Articles

Mutations of the Catalytic Subunit of Class IA PI3K Are Constitutively Active and Confer Factor-Independent Growth to Early Hematopoietic Cells.

Stefan Horn, James McCubrey, Carol Stocking, Lorenz Truemper, Jorg Basecke

Blood (2006) 108 (11): 1455.

https://doi.org/10.1182/blood.V108.11.1455.1455

Published: 2006

Journal Articles

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate

Jörg Cammenga, Stefan Horn, Ulla Bergholz, Gunhild Sommer, Peter Besmer, Walter Fiedler, Carol Stocking

Blood (2005) 106 (12): 3958–3961.

https://doi.org/10.1182/blood-2005-02-0583

Published: 2005

Journal Articles

Dissecting the Molecular Mechanisms of Mutant C/EBPalpha (p30) in Normal and Malignant Human Hematopoiesis.

Jorg Cammenga, MD, Birte Niebuhr, MS/BS, Stefan Horn, PhD, Ruud Delwel, PhD, Carol Stocking, PhD

Blood (2005) 106 (11): 2995.

https://doi.org/10.1182/blood.V106.11.2995.2995

Published: 2005

Journal Articles

The Role of RUNX1 DNA-Binding Mutations in Acute Myeloid Leukemia.

Jorg Cammenga, MD, Gabriela Putz, PhD, Birte Niebuhr, MS/BS, Stefan Horn, PhD, Ulla Bergholz, Frank Buchholz, PhD, Carol Stocking, PhD

Blood (2005) 106 (11): 1373.

https://doi.org/10.1182/blood.V106.11.1373.1373

Published: 2005

NARROW

The Glycogensynthase Kinase 3b (GSK-3β) Is Involved in Leukemic Transformation

The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate

Mutations in the Catalytic Subunit of Class IA PI3K Are Leukemogenic In Vivo.

Mutations of the Catalytic Subunit of Class IA PI3K Are Constitutively Active and Confer Factor-Independent Growth to Early Hematopoietic Cells.

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate

Dissecting the Molecular Mechanisms of Mutant C/EBPalpha (p30) in Normal and Malignant Human Hematopoiesis.

The Role of RUNX1 DNA-Binding Mutations in Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

The Glycogensynthase Kinase 3b (GSK-3β) Is Involved in Leukemic Transformation

The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate

Mutations in the Catalytic Subunit of Class IA PI3K Are Leukemogenic In Vivo.

Mutations of the Catalytic Subunit of Class IA PI3K Are Constitutively Active and Confer Factor-Independent Growth to Early Hematopoietic Cells.

Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate

Dissecting the Molecular Mechanisms of Mutant C/EBPalpha (p30) in Normal and Malignant Human Hematopoiesis.

The Role of RUNX1 DNA-Binding Mutations in Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only